Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) reported promising Phase 2 data for mirikizumab, a treatment for ulcerative colitis (UC), indicating gene expression changes sustained for up to one year post-treatment. Mirikizumab showcased unique transcript changes compared to placebo, correlating with mucosal healing. Additionally, a patient study highlighted bowel urgency improvements, crucial for quality of life. With Phase 3 trials underway for both UC and Crohn's disease, mirikizumab's ongoing development appears to target significant unmet needs in inflammatory bowel disease management.

The EMPEROR-Preserved phase III trial confirmed that Jardiance® (empagliflozin) is the first treatment to significantly reduce the risk of cardiovascular death or hospitalization for heart failure in adults with preserved ejection fraction (HFpEF). Announced on July 6, 2021, by Boehringer Ingelheim and Eli Lilly (NYSE: LLY), the trial's results will be presented at the ESC 2021 congress. Jardiance's efficacy in treating all forms of heart failure was reinforced by previous EMPEROR-Reduced trial results. Regulatory submissions are anticipated in 2021, aiming to address the unmet medical needs in heart failure management.

The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a third-quarter 2021 dividend of $0.85 per share for common stockholders. This dividend will be paid on September 10, 2021, to shareholders recorded by the close of business on August 13, 2021. Lilly remains committed to delivering high-quality medicines and addressing real-world health needs as a leading global healthcare company.

Eli Lilly and Company (NYSE: LLY) announced positive results from its SURPASS-1 trial, showcasing tirzepatide's efficacy in reducing A1C and body weight in adults with type 2 diabetes. After 40 weeks, tirzepatide resulted in A1C reductions of up to 2.07% and weight loss of up to 9.5 kg across three doses, compared to placebo. Most participants achieved A1C levels below 7%, with minimal adverse effects similar to existing GLP-1 treatments. Lilly intends to complete the registration process for tirzepatide by the end of 2021, which marks a significant step in diabetes management.

Eli Lilly's tirzepatide demonstrated superior efficacy in reducing A1C levels and body weight compared to semaglutide in the 40-week SURPASS-2 clinical trial. The study enrolled 1,879 adults with type 2 diabetes, showing A1C reductions of up to -2.46% and weight reductions of up to -12.4 kg across three tirzepatide doses. Notably, 60% of participants on the highest dose achieved significant endpoints without hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, with gastrointestinal issues being the most common side effects. Lilly aims for regulatory submission by the end of 2021.

The FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational antibody, donanemab, for treating Alzheimer's disease. This designation accelerates development for drugs showing significant improvement over existing therapies. Preliminary clinical evidence from the Phase 2 TRAILBLAZER-ALZ trial supports this designation. Lilly plans to submit a biologics license application based on these findings later this year. Donanemab targets modified beta amyloid and is currently undergoing further evaluation in a Phase 3 trial, TRAILBLAZER-ALZ 2.

Eli Lilly has launched the Think Talk Treat Migraine™ initiative aimed at improving migraine care and diagnosis. The initiative addresses the gap in recognizing migraine symptoms and facilitates better communication between patients and primary care providers.
Currently in pilot in four metropolitan areas, it includes tools like a checklist and digital migraine management platform, VEGA™. Despite high prevalence, only a small percentage of migraine sufferers receive adequate treatment. Lilly aims to increase awareness and support effective management of migraine.

Eli Lilly and Company (NYSE: LLY) announced a head-to-head clinical trial comparing Emgality (galcanezumab-gnlm), a monthly injectable, with Nurtec ODT (rimegepant), an oral medication, to assess their effectiveness in preventing migraines. This Phase 4 study will evaluate patients diagnosed with episodic migraine, focusing on the reduction of monthly migraine headache days. The trial aims to provide insights for better treatment decisions. Emgality is recognized for its efficacy in achieving substantial reductions in migraine frequency and has supported over 700,000 patients.